Switzerland Approves Study for Societal Impact of Recreational Cannabis
The pilot study recently received final approval and is anticipated to last five years.
Recently approved by Switzerland’s Federal Office of Public Health, a new pilot study, called “Grashaus Projects,” will test the regulated sale and effects on society of cannabis for recreational purposes (1). It will be a combined effort of the Swiss Institute for Addiction and Health Research (ISGF) and Sanity Group, a medical cannabis company based in Germany (2). According to the press release from Sanity Group (1), this study will be the sixth project involving cannabis to be approved in Switzerland.
The study will reportedly run for five years, is scheduled to start in the fourth quarter of 2023, and will involve up to 3950 participants (1). After potential participants are screened and accepted into the study, they will receive a participation card to legally obtain cannabis (1). Every three to six months afterward, surveys on participants’ consumption habits and health will take place (1). Additionally, the effects on public safety will be analyzed with assistance from the public prosecutor’s office (1).
“The insights gained from the study can contribute to an informed health policy discussion on the responsible use of cannabis and serve as a basis for decisions on long-term regulation,” said Dr. Michael Schaub, Scientific Director of the ISGF and study leader (1). “In addition, we want to investigate whether we can gain better access to high-risk users with, for example, mental health problems, in order to refer them to appropriate cantonal care centers.”
The cannabis products will be obtained by participants from two dispensary stores, both located in the northern canton of Basel-Landschaft and will sell products such as flowers, extracts, and edibles (1). Previous cannabis pilot studies dispensed cannabis through pharmacies or clubs (1). The cannabis will be cultivated and produced by Swiss cultivator SwissExtract (1).
Registration for the study can be found here.
References
- First legal cannabis dispensaries in Europe: Sanity Group and ISGF get green light for a cannabis study in Swiss canton Basel-Landschaft. Sanity Group. October 25, 2023.
- Unlocking the health benefits of cannabinoids https://sanitygroup.com/ (accessed Oct 27, 2023).
- Cannabis-pilotversuch in Basel-landschaft https://grashausprojects.ch/ (accessed Oct 27, 2023).
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
